论文信息 - LB2. Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial - 字舞流文

LB2. Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial

M. Bickel | P. Cahn | J. Mallolas | J. Molina | W. Greaves | G. Hanna | G. Rizzardini | Yan Zhou | Sushma Kumar | Margaret Johnson | C. Hwang | Princy N. Kumar | P. Sklar | Cristiana Morais